degarelix
Selected indexed studies
- Degarelix. (, 2012) [PMID:31643893]
- Degarelix for treating advanced hormone-sensitive prostate cancer. (Cochrane Database Syst Rev, 2021) [PMID:34350976]
- The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. (BJU Int, 2008) [PMID:19035858]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Degarelix. (2012) pubmed
- Degarelix for treating advanced hormone-sensitive prostate cancer. (2021) pubmed
- The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. (2008) pubmed
- ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer. (2023) pubmed
- Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. (2021) pubmed
- Degarelix. (2009) pubmed
- Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer. (2009) pubmed
- Degarelix: a review of its use in patients with prostate cancer. (2014) pubmed
- Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. (2017) pubmed
- Questionable oncologic benefits of degarelix. (2016) pubmed